Publicaciones por equipo

Equipo Dr. Mordoh/Dra. Barrio
Vacunas terapéuticas

  1. 2015

  2. 2013

    • High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. Pizzurro GA, Madorsky Rowdo FP, Pujol-Lereis LM, Quesada-Allué LA, Copati AM, Roberti MP, Teillaud JL, Levy EM, Barrio MM, Mordoh J. Cancer Immunol Immunother. 2013 Jan;62(1):3-15.
    • A word of caution: do not wake sleeping dogs; micrometastases of melanoma suddenly grew after progesterone treatment. Mordoh J, Tapia IJ, Barrio MM. BMC Cancer. 2013 Mar 20;13:132.
    • Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine. Tapia IJ, Aris M, Arriaga JM, Blanco PA, Mazzobre F, Vega J, Mordoh J, Barrio MM. Cryobiology. 2013 Oct;67(2):163-
    • Vacuna terapéutica CSF-470 para melanoma cutáneo. M. Aris; M. M. Barrio; J. Mordoh. Act Terap Dermatol 2013; 36: 40.
  3. 2012

    • Lessons from cancer immunoediting in Cutaneous Melanoma. Mariana Aris, María Marcela Barrio and José Mordoh, Clin Dev Immunol. 2012;2012:192719. Epub 2012 Aug 14.
    • Human macrophages and dendritic cells can equally present MART-1 antigen to CD8+ T cells after phagocytosis of gamma-irradiated melanoma cells. María Marcela Barrio, Riad Abes, Marina Colombo, Gabriela Pizzurro, Charlotte Boix, María Paula Roberti, Emmanuelle Gélizé, Mariana Rodriguez-Zubieta, José Mordoh, Jean-Luc Teillaud. PLoS One. 2012;7(7):e40311.
    • Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. María Paula Roberti, Juan Martín Arriaga, Michele Bianchini, Héctor Ramiro Quintá, Alicia Inés Bravo, Estrella Mariel Levy, José Mordoh, María Marcela Barrio. Cancer Biol Ther. 2012 Sep 1;13(11):1123-40.
    • Capítulo de libro: -CUTANEOUS MELANOMA: MOLECULAR BIOLOGY, RISK FACTORS AND TREATMENT OPTIONS. Mariana Aris, Ivana Jaqueline Tapia, José Mordoh, María Marcela Barrio. Capítulo de libro “Melanoma: Molecular Biology, Risk Factors and Treatment Options, Editor: Richard Schortemeyer III. Nova Science Publishers Inc 2013, 978-1-62808-611-9_eBook

Equipo Dra. Levy
Inmunoestimulación inmunosupresión en tumores sólidos

  1. 2015

  2. 2013

    • Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, Huertas E, Loria FS, Pairola A, Bianchini M, Mordoh J, Levy EM. Innate Immun. 2013 Feb;19(1):76-85
  3. 2012

    • IL-2- or IL-15-activated NK cells enhance Cetuximab-mediated activity against triple-negative breast cancer in xenografts and in breast cancer patients. Roberti MP, Rocca YS, Amat M, Pampena MB, Loza J, Coló F, Fabiano V, Loza CM, Arriaga JM, Bianchini M, Barrio MM, Bravo AI, Domenichini E, Chacón R, Mordoh J, Levy EM. Breast Cancer Res Treat. 2012 Dec;136(3):659-71.

Equipo Dr. Michele Bianchini
Células stem leucémicas

  1. 2014

    • Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy. Arriaga JM, Greco A, Mordoh J, Bianchini M. Mol Cancer Ther. 2014 May;13(5):1369-81.
  2. 2012

    • Combined metallothioneins and p53 proteins expression as a prognostic marker in patients with Dukes stage B and C colorectal cancer. Arriaga JM, Bravo IA, Bruno L, Morales Bayo S, Hannois A, Sanchez Loria F, Pairola F, Huertas E, Roberti MP, Rocca YS, Aris M, Barrio MM, Baffa Trasci S, Levy EM, Mordoh J, Bianchini M. Hum Pathol. 2012 Oct;43(10):1695-703.
    • Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. Arriaga JM, Levy EM, Bravo AI, Bayo SM, Amat M, Aris M, Hannois A, Bruno L, Roberti MP, Loria FS, Pairola A, Huertas E, Mordoh J, Bianchini M. Hum Pathol. 2012 Feb;43(2):197-208.